Selected research
Industry Growth & Trends
Global Angina Pectoris Medication Industry Growth and Trends Forecast to 2032
Market perspective
According to APO Research, the global Angina Pectoris Medication market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for Angina Pectoris Medication is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for Angina Pectoris Medication is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Angina Pectoris Medication is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global companies in the Angina Pectoris Medication market include Sanofi S.A., Novartis AG, Merck & Co., Inc., Eli Lilly and Company, Gilead Sciences, Pfizer Inc., GlaxoSmithKline Plc., Otsuka Pharmaceutical Co., Ltd. and Boehringer Ingelheim International GmbH, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global Angina Pectoris Medication market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Angina Pectoris Medication market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Angina Pectoris Medication market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Angina Pectoris Medication.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global Angina Pectoris Medication market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Angina Pectoris Medication Market by Company
Sanofi S.A.
Novartis AG
Merck & Co., Inc.
Eli Lilly and Company
Gilead Sciences
Pfizer Inc.
GlaxoSmithKline Plc.
Otsuka Pharmaceutical Co., Ltd.
Boehringer Ingelheim International GmbH
Bayer AG
Amgen Inc.
AstraZeneca
Angina Pectoris Medication Segment by Type
Beta Blockers
Calcium Antagonists
Anticoagulants
Anti-Platelets
Others
Angina Pectoris Medication Segment by Application
Hospitals
Clinics
Others
Angina Pectoris Medication Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Angina Pectoris Medication market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Angina Pectoris Medication and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Angina Pectoris Medication.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Angina Pectoris Medication companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Beta Blockers
- Calcium Antagonists
- Anticoagulants
- Anti-Platelets
- Others
Applications
- Hospitals
- Clinics
- Others
Companies covered
- Sanofi S.A.
- Novartis AG
- Merck & Co., Inc.
- Eli Lilly and Company
- Gilead Sciences
- Pfizer Inc.
- GlaxoSmithKline Plc.
- Otsuka Pharmaceutical Co., Ltd.
- Boehringer Ingelheim International GmbH
- Bayer AG
- Amgen Inc.
- AstraZeneca
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global Angina Pectoris Medication Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global Angina Pectoris Medication Market Size by Region (2021-2032)
- 1.4.1 Global Angina Pectoris Medication Market Size by Region (2021-2026)
- 1.4.2 Global Angina Pectoris Medication Market Size by Region (2027-2032)
- 1.5 Key Regions Angina Pectoris Medication Market Size (2021-2032)
- 1.5.1 North America Angina Pectoris Medication Market Size Growth Rate (2021-2032)
- 1.5.2 Europe Angina Pectoris Medication Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific Angina Pectoris Medication Market Size Growth Rate (2021-2032)
- 1.5.4 South America Angina Pectoris Medication Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa Angina Pectoris Medication Market Size Growth Rate (2021-2032)
2 Angina Pectoris Medication Market by Type
- 2.1 Type Introduction
- 2.1.1 Beta Blockers
- 2.1.2 Calcium Antagonists
- 2.1.3 Anticoagulants
- 2.1.4 Anti-Platelets
- 2.1.5 Others
- 2.2 Global Angina Pectoris Medication Market Size by Type
- 2.2.1 Global Angina Pectoris Medication Market Size Overview by Type (2021-2032)
- 2.2.2 Global Angina Pectoris Medication Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global Angina Pectoris Medication Market Size Forecasted by Type (2027-2032)
- 2.3 Global Angina Pectoris Medication Market Size by Regions
- 2.3.1 North America Angina Pectoris Medication Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe Angina Pectoris Medication Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific Angina Pectoris Medication Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America Angina Pectoris Medication Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa Angina Pectoris Medication Market Size Breakdown by Type (2021-2026)
3 Angina Pectoris Medication Market by Application
- 3.1 Type Introduction
- 3.1.1 Hospitals
- 3.1.2 Clinics
- 3.1.3 Others
- 3.2 Global Angina Pectoris Medication Market Size by Application
- 3.2.1 Global Angina Pectoris Medication Market Size Overview by Application (2021-2032)
- 3.2.2 Global Angina Pectoris Medication Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global Angina Pectoris Medication Market Size Forecasted by Application (2027-2032)
- 3.3 Global Angina Pectoris Medication Market Size by Regions
- 3.3.1 North America Angina Pectoris Medication Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe Angina Pectoris Medication Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific Angina Pectoris Medication Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America Angina Pectoris Medication Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa Angina Pectoris Medication Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 Angina Pectoris Medication Industry Trends
- 4.2 Angina Pectoris Medication Industry Drivers
- 4.3 Angina Pectoris Medication Industry Opportunities and Challenges
- 4.4 Angina Pectoris Medication Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by Angina Pectoris Medication Revenue (2021-2026)
- 5.2 Global Angina Pectoris Medication Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global Angina Pectoris Medication Key Company Headquarters & Area Served
- 5.4 Global Angina Pectoris Medication Company, Product Type & Application
- 5.5 Global Angina Pectoris Medication Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global Angina Pectoris Medication Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 Angina Pectoris Medication Players Market Share by Revenue in 2025
- 5.6.3 2025 Angina Pectoris Medication Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 Sanofi S.A.
- 6.1.1 Sanofi S.A. Company Information
- 6.1.2 Sanofi S.A. Business Overview
- 6.1.3 Sanofi S.A. Angina Pectoris Medication Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 Sanofi S.A. Angina Pectoris Medication Product Portfolio
- 6.1.5 Sanofi S.A. Recent Developments
- 6.2 Novartis AG
- 6.2.1 Novartis AG Company Information
- 6.2.2 Novartis AG Business Overview
- 6.2.3 Novartis AG Angina Pectoris Medication Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 Novartis AG Angina Pectoris Medication Product Portfolio
- 6.2.5 Novartis AG Recent Developments
- 6.3 Merck & Co., Inc.
- 6.3.1 Merck & Co., Inc. Company Information
- 6.3.2 Merck & Co., Inc. Business Overview
- 6.3.3 Merck & Co., Inc. Angina Pectoris Medication Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 Merck & Co., Inc. Angina Pectoris Medication Product Portfolio
- 6.3.5 Merck & Co., Inc. Recent Developments
- 6.4 Eli Lilly and Company
- 6.4.1 Eli Lilly and Company Company Information
- 6.4.2 Eli Lilly and Company Business Overview
- 6.4.3 Eli Lilly and Company Angina Pectoris Medication Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 Eli Lilly and Company Angina Pectoris Medication Product Portfolio
- 6.4.5 Eli Lilly and Company Recent Developments
- 6.5 Gilead Sciences
- 6.5.1 Gilead Sciences Company Information
- 6.5.2 Gilead Sciences Business Overview
- 6.5.3 Gilead Sciences Angina Pectoris Medication Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 Gilead Sciences Angina Pectoris Medication Product Portfolio
- 6.5.5 Gilead Sciences Recent Developments
- 6.6 Pfizer Inc.
- 6.6.1 Pfizer Inc. Company Information
- 6.6.2 Pfizer Inc. Business Overview
- 6.6.3 Pfizer Inc. Angina Pectoris Medication Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 Pfizer Inc. Angina Pectoris Medication Product Portfolio
- 6.6.5 Pfizer Inc. Recent Developments
- 6.7 GlaxoSmithKline Plc.
- 6.7.1 GlaxoSmithKline Plc. Company Information
- 6.7.2 GlaxoSmithKline Plc. Business Overview
- 6.7.3 GlaxoSmithKline Plc. Angina Pectoris Medication Revenue, Global Share and Gross Margin (2021-2026)
- 6.7.4 GlaxoSmithKline Plc. Angina Pectoris Medication Product Portfolio
- 6.7.5 GlaxoSmithKline Plc. Recent Developments
- 6.8 Otsuka Pharmaceutical Co., Ltd.
- 6.8.1 Otsuka Pharmaceutical Co., Ltd. Company Information
- 6.8.2 Otsuka Pharmaceutical Co., Ltd. Business Overview
- 6.8.3 Otsuka Pharmaceutical Co., Ltd. Angina Pectoris Medication Revenue, Global Share and Gross Margin (2021-2026)
- 6.8.4 Otsuka Pharmaceutical Co., Ltd. Angina Pectoris Medication Product Portfolio
- 6.8.5 Otsuka Pharmaceutical Co., Ltd. Recent Developments
- 6.9 Boehringer Ingelheim International GmbH
- 6.9.1 Boehringer Ingelheim International GmbH Company Information
- 6.9.2 Boehringer Ingelheim International GmbH Business Overview
- 6.9.3 Boehringer Ingelheim International GmbH Angina Pectoris Medication Revenue, Global Share and Gross Margin (2021-2026)
- 6.9.4 Boehringer Ingelheim International GmbH Angina Pectoris Medication Product Portfolio
- 6.9.5 Boehringer Ingelheim International GmbH Recent Developments
- 6.10 Bayer AG
- 6.10.1 Bayer AG Company Information
- 6.10.2 Bayer AG Business Overview
- 6.10.3 Bayer AG Angina Pectoris Medication Revenue, Global Share and Gross Margin (2021-2026)
- 6.10.4 Bayer AG Angina Pectoris Medication Product Portfolio
- 6.10.5 Bayer AG Recent Developments
- 6.11 Amgen Inc.
- 6.11.1 Amgen Inc. Company Information
- 6.11.2 Amgen Inc. Business Overview
- 6.11.3 Amgen Inc. Angina Pectoris Medication Revenue, Global Share and Gross Margin (2021-2026)
- 6.11.4 Amgen Inc. Angina Pectoris Medication Product Portfolio
- 6.11.5 Amgen Inc. Recent Developments
- 6.12 AstraZeneca
- 6.12.1 AstraZeneca Company Information
- 6.12.2 AstraZeneca Business Overview
- 6.12.3 AstraZeneca Angina Pectoris Medication Revenue, Global Share and Gross Margin (2021-2026)
- 6.12.4 AstraZeneca Angina Pectoris Medication Product Portfolio
- 6.12.5 AstraZeneca Recent Developments
7 North America
- 7.1 North America Angina Pectoris Medication Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America Angina Pectoris Medication Market Size by Country (2021-2026)
- 7.3 North America Angina Pectoris Medication Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe Angina Pectoris Medication Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe Angina Pectoris Medication Market Size by Country (2021-2026)
- 8.3 Europe Angina Pectoris Medication Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Angina Pectoris Medication Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific Angina Pectoris Medication Market Size by Country (2021-2026)
- 9.3 Asia-Pacific Angina Pectoris Medication Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America Angina Pectoris Medication Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America Angina Pectoris Medication Market Size by Country (2021-2026)
- 10.3 South America Angina Pectoris Medication Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Angina Pectoris Medication Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa Angina Pectoris Medication Market Size by Country (2021-2026)
- 11.3 Middle East & Africa Angina Pectoris Medication Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst